Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.
about
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Phase II study of the antibody ...... expressing guanylyl cyclase C.
@en
Phase II study of the antibody-drug conjugate TAK-264
@nl
type
label
Phase II study of the antibody ...... expressing guanylyl cyclase C.
@en
Phase II study of the antibody-drug conjugate TAK-264
@nl
prefLabel
Phase II study of the antibody ...... expressing guanylyl cyclase C.
@en
Phase II study of the antibody-drug conjugate TAK-264
@nl
P2093
P2860
P1476
Phase II study of the antibody ...... expressing guanylyl cyclase C.
@en
P2093
Adedigbo A Fasanmade
Antonio Cubillo Gracian
Carolina Muriel López
David Wright
Frederico Longo Muñoz
Hadi Danaee
Irfan Firdaus
Jean-Luc Van Laethem
Johanna Bendell
Khaldoun Almhanna
P2860
P2888
P304
P356
10.1007/S10637-017-0439-Y
P577
2017-02-11T00:00:00Z